Icure Pharmaceutical Incorporation (175250) — Cash Flow-to-Debt Ratio
Icure Pharmaceutical Incorporation (175250) has a Cash Flow-to-Debt Ratio of -0.05x as of March 2025, meaning its operating cash flow of ₩-3.28 Billion could theoretically repay 0% of its total liabilities (₩64.30 Billion) in one year. Explore 175250 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Icure Pharmaceutical Incorporation Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Icure Pharmaceutical Incorporation across 10 annual periods. Also explore 175250 asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Icure Pharmaceutical Incorporation (2015–2024)
Year-by-year debt coverage analysis for Icure Pharmaceutical Incorporation. For market capitalisation and broader financial context, see market cap of Icure Pharmaceutical Incorporation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | ₩-17.05 Billion | ₩72.62 Billion | ▼ -85.1% |
| 2023 | -0.13x | ₩-13.52 Billion | ₩106.54 Billion | ▼ -51.2% |
| 2022 | -0.08x | ₩-11.28 Billion | ₩134.45 Billion | ▲ +61.7% |
| 2021 | -0.22x | ₩-26.23 Billion | ₩119.69 Billion | ▼ -46.6% |
| 2020 | -0.15x | ₩-12.40 Billion | ₩82.99 Billion | ▼ -197.4% |
| 2019 | -0.05x | ₩-5.94 Billion | ₩118.27 Billion | ▲ +75.0% |
| 2018 | -0.20x | ₩-7.30 Billion | ₩36.31 Billion | ▼ -754.6% |
| 2017 | 0.03x | ₩1.12 Billion | ₩36.43 Billion | ▲ +109.2% |
| 2016 | -0.33x | ₩-4.88 Billion | ₩14.58 Billion | ▼ -3209.8% |
| 2015 | -0.01x | ₩-204.05 Million | ₩20.19 Billion | — |